2-Deoxyglucose induces cell cycle arrest and apoptosisin colorectal cancer cells independent of its glycolysis inhibition.
Level 5 - mechanism / opinion, no new human data
In vitro bench study on cell lines without human data
PubMed 25751508 · doi:10.1080/01635581.2015.1002626
What was done
Authors investigated the molecular anticancer mechanisms of 2-deoxyglucose (2DG) in SW620 colorectal cancer cells in vitro, focusing on cell cycle regulation, mitochondrial apoptosis pathways, and the expression of p21 and p53 in relation to hexokinase inhibition and ATP levels.
What was found
The abstract reports no numerical values, concentrations, or statistical metrics. It qualitatively reports that 2DG induced transient p21 expression, continuous p53 expression, G0/G1 cell cycle arrest, and apoptosis via the mitochondrial pathway. These effects on p21 and p53 protein levels were reported to occur independently of hexokinase inhibition or ATP depletion.
Why it matters
This study shows that 2DG possesses anticancer activity beyond its established role as a glycolytic inhibitor, which may inform rational drug combinations for colorectal cancer.
Limits
This is an in vitro bench study limited to a single colorectal cancer cell line (SW620) without animal or human in vivo data. The abstract provides no quantitative data, dose-response details, or statistical error estimates.
Cited by
- supports 2-deoxyglucose is taken up by cells like glucose, cannot be metabolized to produce ATP, and competitively inhibits hexokinase.